A new report highlights opportunities for the UK to take advantage of its departure from the EU and create UK-specific regulation that puts patients first.
A new report published today by the Regulatory Horizons Council (Thursday 19 August) sets out how the UK could strengthen the regulation of medical devices, learning lessons from the response to the coronavirus (COVID-19) pandemic while boosting the UK’s world-class life sciences sector.
The Regulatory Horizons Council (RHC) is an independent expert committee which identifies the regulation needed to foster technological innovation and provides government with impartial, expert advice on the regulatory reform required to support its rapid and safe introduction. Their new proposals set out how medical devices such as pacemakers or implantable defibrillators should be regulated to ensure we can tackle healthcare challenges effectively, now and in the future.
The report identifies the UK’s departure from the European Union as an opportunity to build a UK-specific regulatory system that puts patients at the heart of decision-making processes – for example by increasing patient representation on expert groups for advice on medical research and devices, and by providing evaluations of medical devices that are easily understandable. It highlights the opportunities now available to the UK, not only to respond more quickly to new advances in technology, but to work with like-minded countries in shaping international regulation.
Life Sciences Minister Nadhim Zahawi said:
It calls for lessons to be learnt from the UK’s COVID-19 response, including addressing delays in medical device approval so that equipment can be authorised effectively and at speed. It also recommends that pandemic preparedness should include fast-track evaluation of new in vitro diagnostics and that reporting of diagnostic tests be transparent and standardised.
The report also highlights opportunities for the UK to take a leading role in the development of international standards, notably in sectors of importance such as AI, while exploring membership of international programmes such as the Medical Device Single Audit Program (MDSAP).
Innovation Minister Lord Bethell said:
It suggests using medical devices as a template to help enable broader UK regulatory reform that improves patient safety and system efficiency by identifying areas where regulatory reform may attract inward investment and growth.
Today’s publication follows the launch of the government’s new Life Sciences Vision, published last month, which outlined ambitions for the sector over the next decade, including the Medicines and Healthcare products Regulatory Agency’s (MHRA) forthcoming consultation on a new regulatory framework for medical devices.
Earlier this year the Medicines and Medical Devices Act 2021, which provides a framework for updating the UK life sciences regime, received Royal Assent. This Act is a milestone in ensuring that after leaving the EU, the UK remains a world-leading regulator by supporting the delivery of the Life Sciences Vision, but also by and ensuring the UK can continue to embrace new health innovations.
The Act allows us to maintain a regulatory system that does what is best for the UK supporting innovation and protecting patient safety. The UK government remains committed to working collaboratively with industry to deliver key ambitions for a future medical devices regime.
Today’s report highlights the opportunity for the UK to show international leadership and become a global centre for medical device regulation.
The Business Secretary Kwasi Kwarteng has written to the Regulatory Horizons Council welcoming the report, and the Department of Health and Social Care will respond in detail to its recommendations following the response to the forthcoming MHRA consultation.